Mersana Therapeutics, Inc.
MRSNNASDAQHealthcare
$29.08
+$0.00(+0.00%)
Market Cap$145363650
P/E Ratio—
52W High$30.39
52W Low$5.21
Mersana Therapeutics, Inc. (MRSN) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · MRSN · as of 2026-06-15
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($69.19M) | ($171.67M) | ($204.21M) | ($170.06M) | ($88.05M) |
| Depreciation & Amort. | $1.63M | $1.52M | $0.93M | $0.85M | $1.01M |
| Stock-Based Comp. | $16.46M | $21.14M | $21.52M | $18.41M | $7.17M |
| Change in Working Capital | ($30.74M) | ($18.76M) | $133.10M | $10.09M | $5.11M |
| Net Cash from Operations | ($82.34M) | ($168.88M) | ($49.36M) | ($139.99M) | ($74.70M) |
| Investing Activities | |||||
| Capital Expenditure | ($0.13M) | ($2.17M) | ($2.20M) | ($0.65M) | ($0.47M) |
| Purchases of Investments | ($133.43M) | ($155.92M) | ($247.52M) | $0.00M | $0.00M |
| Sales of Investments | $145.00M | $277.97M | $97.00M | $0.00M | $37.50M |
| Net Cash from Investing | $11.44M | $119.88M | ($152.72M) | ($0.65M) | $37.03M |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Dividends Paid | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Debt Issued / Repaid | ($2.23M) | ($0.26M) | ($0.27M) | $18.34M | ($0.31M) |
| Net Cash from Financing | $4.09M | $94.67M | $153.02M | $63.65M | $230.41M |
| Free Cash Flow | |||||
| Free Cash Flow | ($82.47M) | ($171.05M) | ($51.56M) | ($140.64M) | ($75.17M) |
| FCF Margin %(computed) | -203.65% | -464.12% | -193.97% | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-15 · USD · M
Explore more Mersana Therapeutics, Inc. data
About Mersana Therapeutics, Inc. (MRSN) Cash Flow Statement
Mersana Therapeutics, Inc. generated operating cash flow of ($0.08B) and free cash flow of ($0.08B) for 2024 — a FCF margin of -203.65%. Capital expenditure was ($0.00B).
Frequently asked questions
MRSN · 4 questionsMersana Therapeutics, Inc. generated free cash flow of ($0.08B) for 2024, up 51.8% year-over-year.
MRSN free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-15